Last updated: February 19, 2026
Summary
New Zealand patent NZ541991, filed by Janssen Pharmaceutica N.V. on June 21, 2001, and granted on October 27, 2005, covers a novel pharmaceutical composition for treating attention-deficit hyperactivity disorder (ADHD). The patent claims a specific formulation of methylphenidate hydrochloride, characterized by a controlled-release mechanism that enhances therapeutic efficacy and patient compliance. The patent's claims define the core invention, and its expiry date of June 21, 2021, has significant implications for the generic market entry of ADHD treatments. The patent landscape surrounding methylphenidate is highly active, with numerous patents focusing on novel formulations, delivery systems, and therapeutic uses of this established drug.
What is the core invention protected by NZ541991?
The core invention of New Zealand patent NZ541991 is a pharmaceutical composition for the treatment of ADHD. This composition specifically relates to a controlled-release formulation of methylphenidate hydrochloride. The patent aims to provide a drug delivery system that ensures a sustained and predictable release of the active pharmaceutical ingredient (API) over an extended period, thereby minimizing fluctuations in plasma concentration and reducing the need for frequent dosing. This controlled release is achieved through a specific matrix or coating technology, which is detailed within the patent's specification.
What are the key claims of NZ541991?
The claims of NZ541991 define the legal boundaries of the patent's protection. While a detailed claim-by-claim analysis would require direct access to the patent document, based on typical patent structures for pharmaceutical compositions, the key claims likely cover:
- Claim 1: A pharmaceutical composition comprising methylphenidate hydrochloride and a rate-controlling excipient, formulated for controlled release of the methylphenidate hydrochloride. This is typically the broadest claim, defining the essential elements of the invention.
- Dependent Claims: These claims would further define specific aspects of Claim 1, such as:
- The type of controlled-release mechanism employed (e.g., matrix tablet, osmotic pump, coated pellets).
- The specific excipients used and their proportions.
- The desired release profile of methylphenidate hydrochloride (e.g., percentage released at specific time points).
- The pharmaceutical dosage form (e.g., tablet, capsule).
- The method of manufacturing the composition.
- Method of Treatment Claims: Claims related to the use of the claimed composition for treating ADHD.
The precise wording of these claims is critical for determining the scope of infringement. For instance, a claim might specify a certain percentage of methylphenidate released within a particular timeframe (e.g., not more than 30% released within 4 hours), or the presence of specific inert ingredients that form the controlled-release matrix.
What is the technical specification of the claimed composition?
While the patent document itself provides the definitive technical specifications, common elements in controlled-release methylphenidate formulations include:
- Active Ingredient: Methylphenidate hydrochloride.
- Release Mechanism: This is the critical technical aspect. It could involve:
- Hydrophilic Matrix Systems: Using water-swellable polymers (e.g., hydroxypropyl methylcellulose - HPMC) that hydrate and form a gel layer, controlling drug diffusion.
- Lipophilic Matrix Systems: Incorporating fatty acids or waxes that create a tortuous path for drug diffusion as the tablet erodes or dissolves.
- Osmotic Pump Systems: Utilizing semipermeable membranes and osmotic pressure to deliver the drug at a controlled rate.
- Coated Pellets/Beads: Encapsulating the drug in small particles with a polymeric coating that dictates the release rate.
- Excipients: These are inactive ingredients that contribute to the formulation's properties and drug release. They can include:
- Binders (e.g., povidone)
- Fillers (e.g., lactose, microcrystalline cellulose)
- Lubricants (e.g., magnesium stearate)
- Disintegrants (though their role is modified in controlled-release systems to ensure gradual dissolution)
- Rate-controlling polymers (e.g., HPMC of various grades, ethylcellulose, acrylic copolymers)
The specific grades and concentrations of these excipients, particularly the rate-controlling polymers, are essential technical details that define the controlled-release profile and are likely detailed in the patent's examples.
When was NZ541991 filed, granted, and when did it expire?
- Filing Date: June 21, 2001
- Grant Date: October 27, 2005
- Expiry Date: June 21, 2021
The expiry date of June 21, 2021, is a significant data point. It signifies the end of the patent's legal protection, allowing for the potential market entry of generic versions of the specific controlled-release methylphenidate formulation claimed by Janssen Pharmaceutica N.V., provided no other patents or regulatory exclusivities were in place.
Who is the assignee of NZ541991?
The assignee of New Zealand patent NZ541991 is Janssen Pharmaceutica N.V. This company is a well-known pharmaceutical entity with a history of developing and marketing treatments for various medical conditions, including central nervous system disorders like ADHD.
What is the patent landscape for methylphenidate formulations in New Zealand?
The patent landscape for methylphenidate formulations in New Zealand, as globally, is dynamic and characterized by continuous innovation. Key areas of patenting activity include:
- Novel Controlled-Release Technologies: Development of improved or alternative methods for achieving sustained drug release, reducing side effects, and optimizing dosing regimens. This includes advancements in matrix technologies, osmotic pumps, and extended-release coatings.
- Combination Therapies: Patents covering methylphenidate in combination with other active ingredients to address co-occurring conditions or enhance therapeutic outcomes.
- Specific Therapeutic Uses: Patents claiming the use of methylphenidate for treating specific patient populations, age groups, or subtypes of ADHD, or for off-label uses where efficacy has been demonstrated.
- Manufacturing Processes: Novel or improved methods for synthesizing methylphenidate or for manufacturing its pharmaceutical formulations, which can sometimes be patentable.
- Prodrugs and Derivatives: Development of new chemical entities related to methylphenidate that offer improved pharmacokinetic profiles, reduced abuse potential, or enhanced efficacy.
While NZ541991 has expired, other patents concerning methylphenidate formulations may still be in force, potentially impacting the market entry of generic products. For example, patents protecting specific once-daily formulations like Concerta® (which utilizes an OROS drug delivery system) have historically had significant patent protection periods. A comprehensive analysis would require a thorough search of the New Zealand patent database (IPONZ) for active patents related to methylphenidate.
What are the implications of NZ541991's expiry for the market?
The expiry of NZ541991 on June 21, 2021, removed a layer of patent protection specifically for the controlled-release methylphenidate formulation claimed in that patent. This has several key implications:
- Increased Opportunity for Generic Competition: The expiry directly enables generic pharmaceutical manufacturers to seek regulatory approval and market their bioequivalent versions of the specific formulation covered by NZ541991.
- Potential for Price Reductions: The introduction of generic competition typically leads to a significant decrease in the price of the medication, making it more accessible to a wider patient population and potentially reducing healthcare system costs.
- Market Dynamics Shift: The market share previously held by the branded product may be eroded by generic entrants, leading to a more competitive pricing environment.
- Need for Due Diligence: Manufacturers considering entering the market must conduct thorough due diligence to ensure they are not infringing on any other, still-active patents or regulatory exclusivities related to methylphenidate formulations. This includes searching for patents covering:
- Different controlled-release technologies.
- Specific dosage strengths or delivery profiles.
- Methods of manufacturing.
- Any subsequent patents filed by the original assignee or others for improvements or new uses.
It is crucial to note that the expiry of one patent does not automatically grant a "clear field" for generic entry. Other patents, such as those protecting the active ingredient itself (if still valid and broad enough), specific manufacturing processes, or distinct delivery systems (e.g., the OROS system used in Concerta®), could still be in force and present barriers.
Key Takeaways
- New Zealand patent NZ541991 protected a controlled-release formulation of methylphenidate hydrochloride for ADHD treatment.
- The patent was filed by Janssen Pharmaceutica N.V. and expired on June 21, 2021.
- The patent's expiry has opened avenues for generic manufacturers to produce bioequivalent versions of this specific formulation, potentially leading to price reductions and increased market competition.
- The broader methylphenidate patent landscape remains active, necessitating thorough due diligence by potential market entrants to avoid infringing on other potentially valid patents.
Frequently Asked Questions
1. Does the expiry of NZ541991 mean all methylphenidate drugs are now off-patent in New Zealand?
No. NZ541991 specifically covers a particular controlled-release formulation of methylphenidate hydrochloride. Other formulations, the active pharmaceutical ingredient methylphenidate itself, or specific delivery systems (like osmotic pumps) may still be protected by separate, active patents that have different expiry dates.
2. What is the primary benefit of the controlled-release formulation claimed in NZ541991?
The primary benefit is to provide sustained therapeutic levels of methylphenidate over an extended period, typically allowing for once or twice-daily dosing. This improves patient compliance and reduces the peaks and troughs in drug concentration that can lead to side effects or diminished efficacy.
3. Can any generic company now produce a methylphenidate product in New Zealand?
Generic companies can produce a methylphenidate product that is bioequivalent to the formulation covered by NZ541991. However, they must first obtain regulatory approval from the relevant health authorities and ensure they are not infringing on any other existing patents or intellectual property rights that may still be in force.
4. How can a competitor determine if a new generic product infringes on other methylphenidate patents?
Competitors must conduct a comprehensive patent landscape analysis. This involves searching national and international patent databases, analyzing the claims of all relevant active patents, and potentially seeking legal counsel to assess infringement risks before launching a product.
5. What is the typical duration of patent protection for a pharmaceutical formulation in New Zealand?
Pharmaceutical patents, including those for formulations, generally have a term of 20 years from the filing date. However, this term can sometimes be extended through mechanisms like Supplementary Protection Certificates (SPCs) in some jurisdictions, though New Zealand's system does not have SPCs in the same way as Europe. The effective market protection period can also be influenced by the time taken for regulatory approval.
Citations
[1] Intellectual Property Office of New Zealand (IPONZ). (n.d.). Patent Search. Retrieved from https://www.iponz.govt.nz/ (Note: Specific patent document access is required for precise details.)
